News
AcariaHealth Named Exclusive Pharmacy for ICLUSIG
Date: 09/25/2019
Takeda Oncology selected AcariaHealth as the exclusive pharmacy to dispense ICLUSIG® (ponatinib) tablets, beginning September 1, 2019. Iclusig is prescribed for the treatment of chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or with a T315I mutation.
As part of the unique partnership between Takeda Oncology and AcariaHealth, and to best support the needs of the ICLUSIG patient population, there are two dispensing models.
One model, called Medically Integrated Dispensing (MID), is facilitated through a new ICLUSIGDirect web portal. The portal gives physicians the ability to purchase and dispense ICLUSIG from their office locations. It also allows hospitals, clinics and broader health systems to purchase ICLUSIG directly to accommodate a patient’s urgent need for this medication.
The second model incorporates traditional specialty pharmacy services. Through this model, a dedicated team of ICLUSIG specialists at AcariaHealth helps patients navigate the complex health care system by reviewing coverage requirements, identifying financial assistance, providing educational resources, and discussing potential side effects. The dedicated ICLUSIG support team provides compassionate care and best-in-class patient service through an individualized approach for each patient with this diagnosis.
“We are excited to partner with Takeda Oncology to address a critical gap in oncology care today - consistent clinical care management, customized to the specific patient. Historically, clinical care in oncology has been standardized and reactive, versus customized and proactive. Our service to ICLUSIG patients addresses this need in a personalized way,” said Steve Granzyk, Vice President of Pharmaceutical Relations and Business Development at AcariaHealth.
“Equally important, our offering treats the whole person through a consultative approach. Placing the patient first has been our mission from day one. We are pleased to have a partner in Takeda Oncology, who also embraces this patient-centric mission,” added Steve.
Patients currently receiving ICLUSIG will get a welcome letter from AcariaHealth with forms and contact information to ensure therapy continues smoothly. Patients will also get a welcome call. This ensures a personalized approach and opportunity to address any patient questions or concerns. Other services include counseling and collaboration with each patient’s health care providers.
The dedicated ICLUSIG team at AcariaHealth will work with patients and caregivers to ensure they receive medication when they need it and where they need it.